Navigation Links
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Date:9/11/2012

MADISON, Wis., Sept. 11, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the second cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.  The second two-patient cohort was successfully dosed with approximately 40 mCi of HOT, triggering enrollment into the third cohort at approximately 60 mCi.  Details of the trial design are available on www.clinicaltrials.gov ID: NCT01495663, or at www.novelos.com in the 'Clinical Trials' section.  Glenn Liu, M.D., Associate Professor of Medicine and Director of the Cancer Therapy Discovery and Development (Phase I) Program at the University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.  Detailed trial results are expected to be presented at a scientific venue at a later date.

"Data from this second cohort indicates that HOT was well-tolerated, without any dose-limiting or sub-dose-limiting toxicities, enabling enrollment of the third cohort as planned," said Dr. Liu.  "We continue to observe selective uptake of HOT in cancerous tumors where it persists for at least 21 days."

"We are pleased with HOT's safety profile and selective cancerous tumor uptake and retention in this second cohort at a dose of approximately 40 mCi," said Kim Hawkins, Vice President of Clinical Development of Novelos.  "We now look forward to evaluating HOT at approximately 60 mCi in cancer patients with advanced solid tumors, as per the trial protocol."

"We expect to begin HOT Phase 2 proof-of-concept trials in the third quarter of 2013 in cancer patients that have significant unmet medical need," said Harry
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  Boston Scientific Corporation (NYSE: BSX ) is ... long-term growth strategies at a meeting with the investment ... . President and Chief Executive Officer Mike Mahoney ... to bring forward meaningful innovation to transform patient care, ... value. "We are focused on addressing ...
(Date:5/1/2015)... 2015 Cambrex Corporation (NYSE: CBM ) reports ... Highlights , Sales increased 18% compared ... foreign currency impact, driven by Innovator products and Controlled Substances. ... in the first quarter of 2014. , GAAP Diluted ... first quarter last year and Adjusted Diluted EPS was $0.29 ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
... Dec. 20, 2011  Advocates working with the disability and ... Senators and House members to help stop a Medicare ... wheelchairs prescribed by their physicians. Seven ... Medicare and Medicaid Services (CMS) for a prepayment review ...
... OSAKA, Japan, Dec. 20, 2011 Takeda Pharmaceutical ... Pharmaceuticals North America, Inc., announced today that the ... (azilsartan medoxomil and chlorthalidone) for the treatment of ... is the only fixed-dose therapy in the U.S. ...
Cached Medicine Technology:Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 2Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 3Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 4FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 2FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 3FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 4FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 5FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 6FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 7
(Date:5/2/2015)... 02, 2015 On Tuesday April 7th, ... (ELCH) gathered to celebrate improvements in patient care. In ... Partners (RVHP), had zero acquired ventilator associated infections, zero ... infections. ELCH was also recently named a Top Performer ... at ELCH credited the teamwork of staff from all ...
(Date:5/2/2015)... the success that Veatch Dental Consulting has had over the ... Alex Shields to the team. With Neida and Alex on ... experience working with dentists to ensure their success. , Neida ... She was certified as dental assistant from Texas State ... showing the importance of oral hygiene to patients, Neida was ...
(Date:5/1/2015)... CA (PRWEB) May 01, 2015 Jusuru ... Award for the successful repositioning of its flagship nutritional ... company brand with a new name, new logo, new ... DSA Ethos Awards are designed to identify and promote ... its best. , “DSA congratulates Jusuru International for ...
(Date:5/1/2015)... 01, 2015 It’s raining bills on Capitol ... proposals to expand federal support for telemedicine. , ... has been working with Congress,” said Jonathan Linkous, CEO of ... the nation is poised to embrace the use of telecommunications ... step in fulfilling ATA’s mission to improve quality, access, equity ...
(Date:5/1/2015)... Florida (PRWEB) May 01, 2015 The Quail ... the American Cancer Society. Since 2001, the Quail Creek Relay ... Relay team host events throughout the year, including their biggest ... the Golf Ball Drop. , Quail Creek Relay for ... was battling cancer. Kate Kerwin, fitness director, states, “I was ...
Breaking Medicine News(10 mins):Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2
... gaps affecting 1 in every 100 Americans , , WEDNESDAY, ... American adults has active epilepsy and more than one-third ... to a Centers for Disease Control and Prevention study ... among more than 120,000 adults in 19 states. ...
... Consumers with hearing loss might think they are saving ... they most likely will be disappointed or could ... to MSU research. , Professor Jerry Punch of ... Love Callaway, a lifelong education alumna and international student ...
... BEIJING, Aug. 13 /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC ... company in the People,s Republic of China,("PRC"), today ... at 10:00,a.m. Eastern Time on Monday, August 18, ... 30, 2008., Joining Dr. Zhongyi Liu, Chairman ...
... Resources to Help ... Alleviate Nursing Shortage, INDIANAPOLIS, Aug. 13 ... program in the city of,Glendale, California, in conjunction with the University ... is the,second program of its kind from Orbis, with the first ...
... have found a mechanism in the immune systems of mice ... turned off. The findings shed light on the processes that ... implications for the development of drugs to increase the immune ... paper appears online today in the journal Nature . ...
... Relational Uncertainty refers to people,s lack of ... new study in the journal Personal Relationships evaluated ... that fluctuations in perceptions of relationships are meaningful ... Haunani Solomon of Pennsylvania State University and Jennifer ...
Cached Medicine News:Health News:Epilepsy Receiving Inadequate Attention 2Health News:Study finds not all hearing aids are created equal 2Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2Health News:Orbis Education Expands Nursing Education Program to Glendale, California 2Health News:Orbis Education Expands Nursing Education Program to Glendale, California 3Health News:NIH scientists find a novel mechanism that controls the development of autoimmunity 2
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
ZyDoc offers a full medical transcription and documentation solution....
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: